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Objectives. We sought o 1) study the effects of FS-069 on car- 
diac and systemic hemodynamic function, myocardial blood flow, 
left ventricular wall thickening and pulmonary gas exchange when 
injected intravenously; and 2) compare the myocardial kinetics 
and microvascular rheology of FS-069 and AIbunex when injected 
directly into a coronary artery. 
Background. FS-069 is a second-generation echocardiographic 
contrast agent composed of perfluoropropane-filled albumin mi- 
crospheres; it is capable of consistent and reproducible myocar- 
dial opacification from a venous injection. 
Methods. Nine dogs were used to study the effects of FS-069 on 
hemodynamic function, pulmonary gas exchange, left ventricular 
wall thickening and myocardial blood flow and to characterize its 
myocardial kinetics when injected intravenously. These dogs were 
also used to compare the myocardial kinetics of FS-069 with those 
of AIbunex during intracoronary injections. Nine Sprague-Dawley 
rats were used to compare the microvascular rheology of these two 
contrast agents, and in vitro modeling was performed to assess 
whether the microvascular findings of FS-069 can explain its 
echocardiographic behavior during direct coronary injections. 
Results. There were no effects of 30 rapid venous injections of 
FS-069 (every 20 s) on cardiac output; mean aortic, pulmonary or 
left atrial pressures; and peak positive and negative first deriva- 
tive of left ventricular pressure (dP/dt). Similarly, there were no 
effects of this agent on radiolabeled microsphere-measured re- 
gional myocardial blood flow, left ventricular wall thickening or 
pulmonary gas exchange. When injected intravenously, the myo- 
cardial transit of this agent resembled a gamma-variate form. 
When diluted FS.069 was injected directly into the coronary 
artery; however, its transit resembled the integral of gamma- 
variate function, with persistent myocardial opacification lasting 
several minutes, which was different from that of Albunex. Intra- 
vital microscopy revealed that, unlike Albunex, when no bubbles 
are entrapped within the microcircnlation after an arterial injec- 
tion, a very small fraction of the diluted, larger FS-069 micro- 
bubbles are entrapped. In vitro modeling confirmed that this 
small fraction of microbubbles can result in persistent myocardial 
opacification. 
Conclusions. FS-069 produces no changes in hemodynamic 
function, myocardial blood flow, left ventricular wall thickening or 
pulmonary gas exchange when injected intravenously in large 
amounts. When diluted FS-069 is injected into the coronary 
artery, a very small fraction of the larger bubbles are entrapped 
within the microcirculation, resulting in a persistent contrast 
effect. Thus, although FS-069 is a safe intravenous echocardio- 
graphic ontrast agent, it cannot provide information on myocar- 
dial blood flow when injected irectly into a coronary artery. 
(J Am Coil Cardiol 1996;28:1292-300) 
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Although several clinical applications have been described for 
myocardial contrast echocardiography, they have been limited 
to the cardiac catheterization laboratory (1-9) and the oper- 
ating room (8,9) because of the unavailability of echocardio- 
graphic contrast agents capable of consistently producing 
myocardial opacification from a venous injection. A major 
limitation of the first-generation echocardiographic contrast 
agents, such as Albunex, is that they contain air, which is highly 
diffusible and rapidly escapes from the bubbles when mixed 
with blood (10). Because the backscatter of a bubble is related 
exponentially to its radius (11), loss of air with a consequent 
decrease in bubble size results in a decrease in its backscatter- 
ing properties. This limitation has been overcome in the 
©1996 by the American Collcgc of Cardiology 0735-1097/96/$15.00 
Published by Elscvier Science lnc. Pll S0735-1097(96)00328-2 
JACC Vol. 28, No. 5 SKYBA ET AL. 1293 
November l, 1996:1292-3(X) FS-069: MYOCARDIAL OPACIFICATION BY VENOUS INJECTION 
Abbreviations and Acronyms 
dP/'dt - first derivative of left ventricular pressure 
DTAF = 5-[(4,6-dichlorotriazin-2-YL)amino]-fluorescein 
ECG = electrocardiogram, electrocardiographic 
second-generation contrast agents by use of high molecular 
weight gases uch as perfluorocarbons (10). These gases do not 
diffuse out of the microbubbles as readily, resulting in mainte- 
nance of their original size and backscattering properties. 
FS-069 is one of the new second-generation c trast agents 
consisting of sonicated albumin microspheres filled with per- 
fluoropropane, which is capable of consistent myocardial 
opacification from a venous injection (12,13). The main aim of 
this study was to determine the effect of this new agent on 
hemodynamic function, myocardial blood flow, left ventricular 
wall thickening and pulmonary gas exchange when injected 
intravenously. A second aim of this study was to compare the 
myocardial kinetics and microvascular theology of FS-069 with 
those of Albunex when injected irectly into a coronary artery. 
Methods  
The experiments were approved by the Animal Research 
Committee at the University of Virginia and conformed to the 
"Position of the American Heart Association on Research 
Animal Use" adopted by the Association in November 1984. 
Nine adult mongrel dogs and nine Sprague-Dawley rats were 
used for the experiments. The dogs were used to assess the 
effect of FS-069 on hemodynamic function, pulmonary gas 
exchange, left ventricular wall thickening and myocardial 
blood flow, as well as to characterize its myocardial kinetics 
when injected intravenously. The animals were also used to 
compare the myocardial kinetics of diluted FS-069 to those of 
Albunex after a bolus injection directly into a coronary artery. 
Intravital microscopy was performed in nine Sprague-Dawley 
rats to compare the microvascular rheology of these two 
contrast agents, and in vitro modeling was performed to 
determine whether the microvascular findings of FS-069 could 
explain its echocardiographic behavior when injected irectly 
into a coronary artery. 
Animal preparations. The dogs were anesthetized with 
30 mg/kg of sodium pentobarbital (Abbott Laboratories), 
intubated and ventilated with a respirator pump (model 613, 
Harvard Apparatus). Additional anesthesia was administered 
during the experiment as needed. Leads were placed on the 
chest wall to obtain an electrocardiographic (ECG) signal. A 
7F catheter was placed in the aorta to record pressure. A 
similar catheter was placed in the left femoral vein to admin- 
ister fluids and drugs, as needed. Catheters were also placed in 
each femoral artery for duplicate reference sample withdrawal 
during radiolabeled microsphere injections and for sampling of 
arterial blood gases. A left lateral thoracotomy was performed, 
and the heart was suspended in a pericardial cradle. 
The first part of the experiment consisted of measuring 
hemodynamic function, myocardial blood flow, left ventricular 
wall thickening and pulmonary gas exchange during repeated 
venous injections of FS-069. For this purpose, micromanometer- 
tipped 7F catheters (model TCB-500, Millar Instruments) 
were placed in the left atrium and left ventricle for the 
measurement of pressures. A 7F flotation catheter (Baxter- 
Edwards Laboratory) was placed in the pulmonary artery for 
measurement of pressures and connected to a computer 
(model 9520A, Edwards Laboratories) for measurement of 
thermodilution cardiac output. The fluid-filled aortic and 
pulmonary artery catheters were attached to fluid-filled trans- 
ducers, which, in turn, were connected to a multichannel 
recorder (model ES2000, Gould Electronics). The catheters 
and the ECG leads were also connected to this recorder. 
The second part of the experiment consisted of comparing 
the myocardial kinetics of FS-069 and Albunex during direct 
intracoronary injections. For this purpose, the proximal por- 
tion of the left anterior descending coronary artery was 
dissected free from the surrounding tissues. The right carotid 
artery was then exposed, and a 12F plastic cannula (model 
1058, C.R. Bard Co.) was inserted into its lumen and secured 
in place with a tie. This cannula was connected toplastic tubing 
(Tygon, Norton Performance Plastics), whose opposite end 
was fastened to a custom-designed metal cannula. The tubing 
was then routed through amicrocomputer-controlled peristal- 
tic pump (model 250l, Harvard Apparatus), and the flow 
through itwas measured using an extracorporeal time-of-flight 
ultrasonic flow probe (model 5C, Yransonics) connected to a 
flowmeter (model T206, Transonics). The tubing was primed 
with blood from the carotid artery, and the left anterior 
descending coronary artery was ligated. The metal cannula 
attached to the tubing was inserted into the left anterior 
descending coronary artery distal to the site of ligation and was 
secured in place with a tie. A power injector (model 3000, 
Liebel-Flarsheim) was used for introduction of microbubbles 
into the tubing. 
The microvascular theology of FS-069 was compared to 
that of Albunex in the spinotrapezius muscle of the rat. Nine 
female Sprague-Dawley rats were anesthetized with an intra- 
muscular injection of a mixture of 1% alpha-chloralose and 
13.3% urethane at a dose of 0.6 ml/100 g of body weight. The 
right carotid artery was cannulated to enable injection of 
microbubbles. The right spinotrapezius muscle was prepared 
for intravital microscopy as previously described (14). The 
muscle was exteriorized, leaving the anterior edge with the 
main feeding artery and vein intact. The exposed muscle was 
continuously superfused with Ringer's solution (pH 7.4) 
warmed to 37°C and saturated with a 5% carbon dioxide and 
95% nitrogen gas mixture. The muscle was spread over a 
transparent coverslip on a hollow pedestal to allow visualiza- 
tion with a microscope. After the dissection was complete, the 
preparation was allowed a minimum of 15 rain to stabilize 
before observations were drawn. 
Hemodynamic data acquisition. Hemodynamic data were 
acquired using the multichannel recorder, which was con- 
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Figure 1. Size distributions and concentrations f (A) FS-069 and (B) 
Albunex. 
nected to an 80386-based personal computer (model 2531, 
DTK Inc.) through an eight-channel analog-to-digital con- 
verter (DAS 16/16F, Keithley-Metrabyte). Data were acquired 
at 200 Hz and displayed in real time using data acquisition 
software (LabTech Notebook). These data were transferred to
RS/1 (Bolt Beranek, and Newman), resident on a VAX-4000 
(Digital Equipment Corp.) for later analysis. Five-second 
samples of the ECG and aortic, pulmonary artery, left atrial 
and left ventricular pressures were acquired at 20-s intervals 
before, during and after the FS-069 injection sequence. Left 
ventricular end-diastolic pressure and peak positive and nega- 
tive left ventricular dP/dt were derived using a custom- 
designed program. 
Two-dimensional echocardiography. Two-dimensional echo- 
cardiography was performed using a phased-array s stem with a 
5-MHz transducer (RT5000, General Electric Medical Systems). 
Gain settings were optimized at the beginning of the experiment 
and were held constant throughout. A maximal dynamic range of 
72 dB was used. A saline bath served as an acoustic interface 
between the heart and the transducer. Imaging was performed at 
the midpapillary muscle short-axis level with the transducer fixed 
in a permanent position by means of a clamp attached to the 
procedure table. Data were recorded on 1.25-cm S-VHS video- 
tape using a S-VHS video recorder (Panasonic AG-7350, Mat- 
sushita Electric). 
The optimal venous dose of FS-069 (Molecular Biosystems, 
Inc.) was determined in the closed chest animal (see protocol). 
A histogram of its size distribution is depicted in Figure 1A. 
For studying the effects on hemodynamic function, myocardial 
thickening and pulmonary gas exchange, FS-069 was adminis- 
tered intravenously using a programmable injector pump 
(model 22, Harvard Apparatus) at a rate of 0.3 ml/s at 20-s 
intervals. To compare the myocardial kinetics of FS-069 and 
Albunex after an intracoronary injection, the former was 
diluted in normal saline to a final dilution of 1:50. The 
myocardial kinetics of 0.25 _+ 0.14 ml of diluted FS-069 was 
compared to those of 0.225 + 0.12 ml of undiluted Albunex 
(Molecular Biosystems, Inc), the size distribution of which is 
depicted in Figure lB. A saline flush was used with the 
injections o that the total volume injected was always 3 ml, 
and the injection rate was fixed at 1 ml/s for all intracoronary 
injections, resulting in identical input functions for each agent. 
Imaging was initiated a few seconds (5 to 10) before injection 
of microbubbles and was continued until after their visual 
disappearance from the myocardium. 
Analysis of echocardiographic data. Echocardiographic 
images from the in vivo and in vitro experiments were trans- 
ferred from videotape into the digital memory of an image 
processing workstation (Mipron, Kontron) and analyzed using 
custom-designed software (15). For the in vivo experiments, 
consecutive nd-diastolic frames, beginning 4 to 5 frames 
before the appearance of contrast agent until after its clear- 
ance from the myocardium, were selected and aligned using 
cross correlation. The time-intensity data from intracoronary 
injections were fit to a gamma-variate function (y = Ate -"t) 
for Albunex and to the integral of the gamma-variate function 
(y = A[1 - (1 + oa)e ~t]) for FS-069 (15). Venous injections 
of FS-069 were better suited to a gamma-variate fit. Images 
obtained at each concentration from the in vitro experiment 
were fit with the integral of a gamma-variate function. 
At sampling times 4 rain apart, three consecutive nd- 
systolic and end-diastolic images were analyzed for left ven- 
tricular wall thickening. The epicardial and endocardial out- 
lines of the left ventricle in these three sets of images were 
traced, and 64 equidistant points along these outlines were 
automatically defined and connected by the computer using a 
minimal distance rule. The percent wall thickening was calcu- 
lated for each chord in each set of images using the equation: 
%wall thickening = (end-systolic chord length - end-diastolic 
chord length)/(end-diastolic chord length). The average thick- 
ening of all 64 chords from all three sets of images were used 
to derive the mean percent left ventricular wall thickening for 
each stage. 
Myocardial blood flow measurement. Approximately 2 × 
106 of ll-/~m radiolabeled microspheres (Dupont Medical 
Products), suspended in 4 ml of 0.9% saline solution and 
0.01% polysorbate 80 (Tween 80), was injected into the left 
atrium in a random order at 4-min intervals. Reference 
samples were withdrawn from the femoral artery over 130 s 
using a constant-rate withdrawal pump (model 944, Harvard 
Apparatus). At the end of the experiment, he heart was cut 
into -250 pieces. Both these tissue samples and the arterial 
reference samples were counted in a well counter with a 
multichannel analyzer (model 1282, LKB Wallac). Corrections 
were made for activity spilling from one window to the next 
using a custom-designed computer program. Flow to each 
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sample was calculated using the equation: Om= (Cmx Qr)/Cr, 
where Qm = myocardial f ow (ml/min), Cm = tissue counts, 
Q,. = rate of arterial sample withdrawal (ml/min) and Cr = 
counts in the arterial reference sample (16). The average 
myocardial blood flow to the heart at each stage was calculated 
by averaging flows to all myocardial segments. 
Blood gas analysis. Samples used for blood gas analysis 
were collected from the femoral artery through a 7F catheter 
4-rain apart. Approximately 2.0 ml of arterial blood was 
withdrawn using a glass syringe (3-ml Multifit, Becton- 
Dickinson) containing a small quantity of heparin sodium. The 
glass syringes were packed in an ice-filled container, and each 
sample was analyzed within 1 h of withdrawal using a blood gas 
and pH analysis machine (model 158, Ciba-Corning). 
Intravital microscopy. The microvascular rheology of the 
microbubbles was studied with a high magnification micro- 
scope (Zeiss Customized ACM, Zeiss Inc.) mounted over the 
exteriorized spinotrapezius muscle preparation. A water im- 
mersion objective (×63) with numerical perture (0.90 U) was 
used. The optical resolution of this system is 0.4/zm. Data were 
recorded using a video camera (model CCD-72, Dage-MTI 
Inc.) mounted on the microscope and connected to a S-VHS 
recorder (model AG-1730, Matsushita). An image intensifier 
(Genllsys, Dage-MTI Inc.) resulted in a final magnification of 
x2,200. Measurement were performed off-line using a video 
caliper (model 305R, Vista Electronics) with the images dis- 
played on a high resolution (0.2 tzm/line) monitor (model 
PVM-137, Sony Corp.). 
In vitro experiment. An in vitro experiment was performed 
to determine whether the number of static microbubbles per 
tissue volume observed in the intravital microscopy studies was 
of a high enough concentration to account for the persistent 
myocardial opacification observed during echocardiography 
following intracoronary injections of FS-069. A glass beaker 
was filled with 4 liters of 0.9% saline solution. The echocar- 
diographic transducer was fixed 2 cm into the saline near the 
center of the beaker to which various doses of FS-069 were 
introduced. A magnetic stirrer at the bottom of the beaker 
ensured thorough mixing of the microbubbles with the saline. 
Images were acquired for 10 s beginning at the time of 
injection and stored on videotape for later analysis. 
Protocols. For determining the intravenous dose of FS-069 
required for optimal myocardial opacification, closed chest 
echocardiographic examination was performed in the dogs 
before the lateral thoracotomy. FS-069 was injected in the 
femoral vein beginning at a dose of 0.3 ml with increments of
0.1 ml up to a maximal dose of 0.8 ml. Three minutes was 
allowed between i jections for most of the agent o be cleared 
from the left ventricular cavity. From these injections, the 
optimal intravenous dose was determined for each dog based 
on the visual assessment of myocardial opacification, which 
was then used for all subsequent injections. 
The dogs were then instrumented for the first part of the 
experiment, and beginning 4 min before the first injection of 
FS-069, continuous echocardiographic recording was initiated. 
Also beginning at this time, and at every minute thereafter, 5 s 
of hemodynamic data were sampled. Three minutes before the 
first injection of FS-069, radiolabeled microspheres were in- 
jected, blood samples were drawn for blood gas analysis and 
cardiac output was measured. These measurements were re- 
peated at 4-rain intervals. At time zero, FS-069 injections were 
initiated and repeated at 20-s intervals for 10 rain. Hemody- 
namic data acquisition and echocardiographic recording ended 
5 min after the last injection of FS-069. A single venous 
injection of FS-069 was given to study the myocardial kinetics 
of FS-069 from this route. 
For the second part of the experiment, Albunex and FS-069 
microbubbles were separately injected into the cannulated left 
anterior descending coronary artery at four different flow rates 
in each dog (ranging from 15 to 77 ml/min) to study their 
myocardial kinetics when injected through this route. At the 
end of the experiment, he heart was excised for myocardial 
blood flow analysis. 
For intravital microscopy, both Albunex and FS-069 micro- 
bubbles were labeled with 90% DTAF (5-[(4,6-dichlorotriazin- 
2-YL)amino]-fluorescein (Sigma Chemical) as previously de- 
scribed (17). Before injecting the microbubbles, an area of the 
spinotrapezius muscle qual to 24 adjacent fields of view, each 
containing a clear view of the microvasculature throughout the 
tissue thickness, was previewed. Several transverse arteriole- 
collecting venule units were present within the region of 
observation; therefore, any potential biasing from topologic 
heterogeneity was negligible. The light source in the micro- 
scope was then switched from transillumination to epi- 
illumination at a peak wavelength of 510 nm, which is an 
appropriate excitation wavelength for DTAF. Approximately 
0.17 × 109 microbubbles of Albunex or 0.30 x 109 micro- 
bubbles of FS-069 were injected into the carotid artery over 5 s. 
The number of static-labeled microbubbles in the previously 
mapped fields of view was then determined. 
Statistical methods. Data are expressed as mean value _+ 
1 SD. Interstage comparisons were performed using repeated 
measures analysis of variance, and differences between indi- 
vidual stages were compared using the Student t test with the 
Bonferroni correction. Comparisons between echocardio- 
graphic and other measurements were made using linear 
regression analysis. Statistical significance was defined as p < 
0.05 (two-sided). 
Resul ts  
Effect of FS-069 on hemodynamic function, myocardial 
blood flow, left ventricular wall thickening and pulmonary gas 
exchange. Figures 2 and 3 summarize the effect of the 30 doses 
of FS-069 injected over 10 rain (a dose every 20 s) on hemo- 
dynamic function, myocardial blood flow and pulmonary gas 
exchange. The variables are plotted beginning 3rain before the 
first injection of FS-069 to 5 rain after the final injection. There 
were no significant changes in the mean aortic and pulmonary 
artery pressures (Fig. 2A), left atrial and left ventricular 
end-diastolic pressures (Fig. 2B) and peak positive and nega- 
tive left ventricular dP/dt (Fig. 2C) over the 19 samples 
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Figure 2. Effect of FS-069 injected every' 20 s on mean aortic and 
pulmonary' artery' (PA) pressures (A), left ventricular (LV) end- 
diastolic and mean left atrial pressures (B) and peak positive and peak 
negative first derivative of left vcntricular pressures (dP/dt) (C). These 
measurements were performed every 1 min starting 3 min before the 
first injection of FS-069 and continuing for 5 min after the last 
injection. See text for details. 
obtained at l-rain intervals in all nine dogs. Similarly, no 
significant changes were found in the cardiac output and 
myocardial blood flow (left and right y axes, respectively, in
Fig. 3A), echocardiographically determined percent left ven- 
tricular wall thickening (Fig. 3B), partial pressure of oxygen or 
pH (Fig. 3C). The partial pressure of carbon dioxide and 
HCO 3 also did not show significant changes. The mean cumu- 
lative dose of FS-069 for this part of the protocol in each dog 
was 15 ml. The mean dose required for myocardial opacifica- 
tion from venous injection was 0.5 ml. 
Myocardial kinetics of FS-069. After venous injection, the 
myocardial kinetics of FS-069 approximated a gamma-variate 
form and indicated an unimpeded wash-in and wash-out of the 
bubbles throughout he myocardium. A direct injection of 
diluted FS-069 into the left anterior descending coronary 
artery, however, resulted in persistence of microbubbles within 
the myocardium. Figure 4A depicts data from one dog at four 
different flow rates. There is no relation between bubble 
wash-out and left anterior descending coronary artery flow. In 
comparison, as previously demonstrated (18), a direct intra- 
coronary injection of Albunex resulted in time-intensity curves 
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Figure 3. Effect of FS-069 injected every 20 s on cardiac output (CO) 
and myocardial blood flow (MBF) (A), percent left ventricular (LV) 
wall thickening (B) and partial pressure of oxygen (pO2) and pH (C). 
These measurements were performed every' 4 min starting 3 min 
before the first injection of FS-069 and continuing for 3 rain after the 
last injection. See text for details. 
with a characteristic gamma-variate form and mean transit 
rates that correlated linearly with flow. Figure 4B illustrates 
Albunex time-intensity curves in the same dog using the same 
four flow rates as depicted in Figure 4A. A gradual disappear- 
ance of FS-069 microbubbles from the myocardium was noted 
over about 5 min. Similar results were obtained from all nine 
dogs. 
Microvascular rheology of FS-069 versus Albunex. To bet- 
ter understand the persistence of FS-069 in the myocardium, 
the rheology of FS-069 was studied in the rat's spinotrapezius 
muscle using intravital microscopy. Of the nine rats, one died 
during preparation, one was injected with labeled Albunex 
only, three were injected with labeled FS-069 only and four 
were injected with labeled Albunex followed by labeled FS- 
069. 
No bubble entrapment in the microcirculation was noted 
despite 10 injections of Albunex in five rats. When the proce- 
dure was repeated using FS-069, however, 1 to 15 static 
bubbles (mean 4.7, median 3) were found in the 24 fields of 
view after the first injection. In most cases, capillary vessels or 
small arterioles were observed to be "plugged" by a micro- 
bubble, as evidenced by the lack of erythrocyte flux in the 
vessel (Fig. 5). In a few cases, the plugs were found in small 
venules, typically at stagnation points in convergent bifurca- 
tions. Subsequent injections of FS-069 resulted in greater 
numbers of plugs. 
The largest FS-069 microbubbles caused plugging. Of the 
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Figure 4. Time-intensity plots obtained from the anterior myocardium 
after direct left anterior descending coronary artery injections at four 
different flow rates in a group I dog using (A) diluted FS-069 and (B) 
diluted Albunex. See text for details. Circles = 20 ml/min; solid 
triangles = 70 ml/min; squares = 52 ml/min; open triangles = 
35 ml/min. 
104 plugs found, 33 of the most clearly focused, along with the 
microvessel containing them, were chosen for measurement: 
28 were found to be elongated with a mean long-axis length 
(along the direction of the vessel) of 12.2 + 2.9 /~m. The 
maximal long-axis plug length recorded was 19.4/~m, whereas 
Figure 5. Example of a field of view on intravital microscopy showing 
plugged FS-069 microbubbles ata magnification of × 1,375. The upper 
bubble had a short-axis diameter of 7.0/~m, a long-axis diameter of 
7.4 /~m and a vessel diameter of 5.2 ~m. The lower bubble had a 
short-axis diameter of 7.9/~m, a long-axis diameter of 8.4 p,m and a 
vessel diameter of 6.4 ~m. 
t 
the minimum was 6.9/~m. The mean short-axis width (perpen- 
dicular to the vessel direction) was 9.4 _+ 2.2 p~m with maximal 
and minimal short-axis widths of 15.5 and 5.17 ~m, respec- 
tively. The mean microvessel diameter containing these plugs 
was 6.1 -- 1.2 ,am, which is consistent with normal measures of 
rat skeletal muscle capillary vessels (19). Microvessel diame- 
ters were measured as close as possible to the site of the 
plugged bubbles. Distention of the walls of the microvessel due 
to the lodged bubble was not uncommon. The mean amount of 
distention, determined by subtracting the diameter of the 
nondeformed vessel from the short-axis bubble width, was 
found to be 3.3 _+ 2.1 ~m. 
Results of in vitro modeling. Figure 6 (left) illustrates the 
nonlinear relation between microbubble concentration and 
video intensity for the echocardiographic system used in this 
study. To ascertain whether the prolonged myocardial opaci- 
fication after intracoronary injection results from minimal 
plugging, calculations based on combined ata from the intra- 
vital microscopy study and the in vitro experiment were 
performed. The diameter of a single field of view for the 
microscope used in the intravital observations (×63 objective) 
was 0.27 ram. Thus, the area of the field of view is 
(0.27)-~7r 
- 0.057 mm -~ 
4 
The average muscle thickness in the area used for our 
observations was 250/~m (0.250 ram) (20), so the volume of the 
tissue is 0.0143 mm 3 per field of view. A 6 × 4 region was 
scanned for each FS-069 injection; thus, the total volume 
corresponding to 24 fields of view is 0.3435 mm 3. If the mean 
number of plugs found in this volume of tissue is four, then the 
corresponding concentration of microbubbles in tissue can be 
determined as follows: 
4 bubbles 1,000 mm 3 
0.3435 mm 3 × 1 cm 3 ~ 11,644 bubbles/cm 3 
By applying this result to the concentration versus video 
intensity profile determined in the in vitro study (Fig. 6, left), 
one can see that the video intensity corresponding to this 
concentration of microbubble plugs is -60  gray-scale units. 
Discuss ion  
Ideal properties of a venous echocardiographic contrast 
agent. The major determinant of backscatter from bubbles 
insonified at nonresonating frequencies is their size (11). It 
becomes obvious from Figure 6 (right), which depicts the 
relation between microbubble size and ultrasound backscatter, 
that even a small decrease in bubble size can result in a marked 
decrease in backscatter. There are many factors that can cause 
a decrease in bubble size, including the molecular weight and 
diffusibility of the gas contained in the microbubbles (10), the 
partial pressures of gases in the bubbles in relation to those of 
the same gases in blood (21) and the ambient pressure in the 
in vivo system (22). The first-generation contrast agents, such 
as Albunex, are most susceptible to these factors. The gases 
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Figure 6. Left, Relation between microbubble concentration f bub- 
bles versus video intensity hat demonstrates why a small number of 
microbubbles ntrapped in tissue can result in a bright and persistent 
contrast effect. Right, Relation between microbubble size and back- 
scatter. Curve A - size distribution f microbubbles ade ak; k = t).5: 
average d - 4/,m). Curve B = backscatter [c~(de dk)d('] (1 1). 
contained in these bubbles (mainly nitrogen and oxygen) are 
highly diffusible and soluble and leak out of the bubbles when 
they are mixed with blood, thus decreasing their size and 
backscatter. Consequently, conditions associated with pro- 
longed pulmonary transit of the bubbles, such as a low cardiac 
output (23), result in lesser contrast effect in the left ventricular 
cavity after a venous injection of these bubbles. 
FS-069 is a modification of Albunex containing perfluoro- 
propane, ahigh molecular weight gas that is less diffusible than 
air (10). The concentration of microbubbles in FS-069 is 
almost twice that of Albunex, and it also has a greater 
proportion of larger bubbles (Fig. 1). This agent consistently 
produces myocardial opacification irrespective of the duration 
of contact with blood (12,13). As noted in our study, the dose 
of FS-069 required for optimal myocardial opacification from a 
venous injection in the dog is -0.5 ml. 
Successful transpulmonary passage is essential for a venous 
contrast agent o opacify the left heart, and bubbles larger than 
the pulmonary capillary, vessels cannot cross the lungs. A high 
concentration of large bubbles can also cause pulmonary 
microcirculatory blockage, resulting in hypoxia, increased pul- 
monary vascular esistance and decreased forward flow (car- 
diac output). For this reason these variables were measured in
our study. Despite 30 rapidly injected consecutive doses, each 
adequate to cause myocardial opacification, there were no 
changes in pulmonary gas exchange, pulmonary artery, pressure 
or cardiac output, indicating that any larger bubbles present in 
FS-069 and trapped within the pulmonary microcirculation are 
too sparse to cause any changes in these variables. 
Once the bubbles traverse the lungs and enter the left heart. 
they should not cause any changes in systemic and cardiac 
hemodynamic function. Despite 30 consecutive rapid doses of 
FS-069, no changes in aortic pressure or peak positive and 
negative left ventricular dP/dt were noted. Additionally, no 
changes in radiolabeled microsphere-measured myocardial 
blood flow were seen. These results indicate that the bubbles, 
after pulmonary transit, do not cause microcirculatory imbal- 
ances within the myocardium. The lack of any effect on left 
ventricular wall thickening also supports the absence of any 
direct myocardial depressant effect or any indirect effect on 
myocardial mechanics modulated through abnormalities in- 
duced in myocardial blood flow. 
Myocardial kinetics of mierobubbles. There are two main 
approaches that can be used to measure myocardial perfusion 
using tracers that reside entirely within the intravascular space 
(24). One approach is using a deposit racer that becomes 
completely entrapped within the microcirculation, as is the 
case with radiolabeled microspheres that are lodged within the 
arterioles (16). The number of microspheres per unit of tissue 
then provides an estimate of flow to that tissue. This approach 
is currently impractical for myocardial contrast echocardiogra- 
phy using venous injection, because bubbles large enough to be 
entrapped in the coronary, arterioles cannot cross the lungs. 
The number of microbubbles that get entrapped within the 
arterioles required to produce a contrast effect on echocardi- 
ography in closed chest humans may also be large enough to 
cause significant hemodynamic effects. Although rest myocar- 
dial blood flow may not be affected by entrapment ofbubbles 
in normal subjects because of the abundant coronary flow 
reserve, it may have adverse ffects in patients with coronary 
artery disease who have partial or complete xhaustion offlow 
reserve. It is conceivable that with more sensitive ultrasound 
methods uch as harmonic imaging (25,26), significantly fewer 
bubbles may be required within the myocardium to produce 
adequate opacification, allowing measurement of myocardial 
blood flow from a direct left heart injection of bubbles that are 
fully entrapped within the myocardial microcirculation. 
The second approach for measuring myocardial blood flow 
is using tracers that freely traverse the microcirculation and 
recording their transit through tissue. Variables of time- 
intensity, curves thus obtained can then be used to measure 
myocardial perfusion (flow and volume) (18,24). It appears 
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from our study that when FS-069 is injected intravenously, its 
transit through the myocardium simulates a gamma-variate 
form. When injected directly into the coronary artery, how- 
ever, persistence of myocardial opacification is noted. To 
better understand the differences in myocardial kinetics of 
FS-069 when injected intravenously and into the coronary 
artery, we studied this agent using intravital microscopy and 
compared it with Albunex, We previously demonstrated that 
Albunex microbubbles have an intravascular rheology similar 
to that of red blood cells, both during intravital microscopy 
(17) and when these bubbles are injected directly into the 
coronary artery (18). As expected, we found that Albunex 
microbubbles were not trapped in the microcirculation of the 
rat's spinotrapezius muscle. Although the majority of the 
diluted FS-069 microbubbles also was not trapped, a few larger 
bubbles were. In vitro modeling confrmed that the persistent 
myocardial opacification seen after coronary injections can 
occur from the plugging of the microcirculation by a few 
bubbles. 
These results explain the disparate myocardial kinetics of 
FS-069 when injected intravenously versus into the coronary 
artery. Unlike the intracoronary setting, the relatively larger 
bubbles are likely filtered by the lungs when injected intrave- 
nously. As shown in Figure 1, larger bubbles are more common 
in FS-069 than in Albunex, which may explain the differences 
in myocardial kinetics of the two agents when injected into the 
coronary artery. The few large bubbles present in Albunex may 
either be destroyed uring injection or become smaller after 
contacting blood. Their absence in the microcirculation studies 
and in the myocardium during arterial injections supports 
these possibilities. 
Our results also indicate that direct coronary injections of 
FS-069 are unlikely to provide information on myocardial 
blood flow. They are not suitable as deposit racers because 
they are not all trapped within the myocardium. Tracer kinetics 
also cannot be used with these bubbles to determine myocar- 
dial blood flow because a few of them cause persistent 
opacification, precluding the assessment oftime-intensity data. 
Because only a few of the bubbles are lodged within the 
myocardium, they are unlikely to cause harmful effects. Be- 
cause they reside within the myocardium for several minutes, 
they could provide information on the spatial distribution of 
myocardial perfusion. Although Albunex is superior in terms 
of assessing myocardial blood flow after a direct bolus injection 
into the coronary artery (18,27), its transit hrough the myo- 
cardium under these conditions may be too rapid to provide an 
adequate on-line assessment of the spatial distribution of 
myocardial perfusion. 
Study limitations. Ultrasound was used in this study 1) to 
determine the optimal dose of FS-069 required for adequate 
myocardial opacification from a venous injection in a close- 
chest dog; 2) to measure the effect of FS-069 on left ventricular 
wall thickening; and 3) to study the myocardial kinetics of 
FS-069 and Albunex. Microbubbles are destroyed by ultra- 
sound when they are insonified at their resonating frequency 
(25,26). We have shown that FS-069 microbubbles are de- 
stroyed at frequencies of 2 to 3 MHz, with little or no 
destruction atfrequencies of5 MHz or higher (26). The use of 
a 5-MHz transducer, therefore, allowed us to study micro- 
bubbles both in vivo and in vitro without destroying them. We 
also recently found that a venous injection of 0.5 ml of FS-069 
is more than adequate for myocardial perfusion in humans 
during intermittent harmonic imaging (13). We studied the 
hemodynamic effects of multiple injections of FS-069 in this 
study because in the clinical setting multiple injections are 
likely to be performed for image acquisition in different views 
both before and after interventions. Although Albunex has 
been approved by the Food and Drug Administration as a 
venous agent, one of its off-label applications i intracoronary 
injections (28), for which it has been shown to be safe in both 
dogs and humans (29,30). The safety of intracoronary injec- 
tions of FS-069 has not been studied. 
Conclusions. This study describes the effects of FS-069, a 
new second-generation echocardiographic contrast agent, on 
cardiac and systemic hemodynamic function, myocardial blood 
flow, left ventricular wall thickening and pulmonary gas ex- 
change during and after venous injections of 30 consecutive 
doses performed every 20 s. It also characterizes the myocar- 
dial kinetics of this agent when injected both intravenously and 
into the coronary artery and explains why this agent, unlike 
Albunex, cannot provide information on myocardial blood flow 
when it is injected into the coronary artery. This study also 
provides a framework for the evaluation of other new echo- 
cardiographic contrast agents that are being developed and will 
be developed in the future. 
We acknowledge the assistancc of Suad lsmail, MD, during conduction of the in 
vivo experiments, and the helpful critique of the manuscript by Jonathan 
Lindner, MD. 
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